Activation of the coagulation system in the alveolar space plays an important role in the pathogenesis of interstitial lung disease (ILD) and pulmonary fibrosis. The protein C (PC) pathway is the main modulator of coagulation activation. This study evaluated whether dysfunction of the PC pathway is associated with increased collagen synthesis in the intraalveolar space of patients with ILD. This study comprised 22 patients with ILD; of these, five had idiopathic pulmonary fibrosis (IPF), nine had sarcoidosis-associated ILD, and eight had collagen vascular disease-associated ILD (CVD-ILD). Thrombin&mdash; antithrombin complex (TAT) was measured as a marker of coagulation activation. As markers of the PC pathway activity, the concentration of activated PC-PC inhibitor (APC-PCI) complex and the APC-PCI/PC ratio were measured and, as a marker of collagen synthesis, the concentration of aminotermi-nal propeptide of type III procollagen (PIIINP) was measured in bronchoalveolar lavage fluid (BALF) of ILD patients. TAT was significantly increased in BALF from ILD patients as compared to control subjects. The concentrations of PIIINP were significantly elevated in patients with ILD as compared to healthy subjects. In contrast, the concentration of APC-PCI and the values of APC-PCI/PC ratio were significantly decreased in BALF from patients with ILD. BALF concentration of PIIINP was significantly and inversely correlated with the concentration of APC-PCI and with the APC-PCI/PC ratio. These findings suggest that dysfunction of the protein C pathway may have important physiopathologic implications in the development of pulmonary fibrosis in ILD.
Summary: Activation of the coagulation system in the alveolar space plays an important role in the pathogenesis of interstitial lung disease (ILD) and pulmonary fibrosis. The protein C (PC) pathway is the main modulator of coagulation activation. This study evaluated whether dysfunction of the PC pathway is associated with increased collagen synthesis in the intraalveolar space of patients with ILD. This study comprised 22 patients with ILD; of these, five had idiopathic pulmonary fibrosis (IPF), nine had sarcoidosis-associated ILD, and eight had collagen vascular disease-associated ILD (CVD-ILD). Thrombin&mdash; antithrombin complex (TAT) was measured as a marker of coagulation activation. As markers of the PC pathway activity, the concentration of activated PC-PC inhibitor (APC-PCI) complex and the APC-PCI/PC ratio were measured and, as a marker of collagen synthesis, the concentration of aminotermi-nal propeptide of type III procollagen (PIIINP) was measured in bronchoalveolar lavage fluid (BALF) of ILD patients. TAT was significantly increased in BALF from ILD patients as compared to control subjects. The concentrations of PIIINP were significantly elevated in patients with ILD as compared to healthy subjects. In contrast, the concentration of APC-PCI and the values of APC-PCI/PC ratio were significantly decreased in BALF from patients with ILD. BALF concentration of PIIINP was significantly and inversely correlated with the concentration of APC-PCI and with the APC-PCI/PC ratio. These findings suggest that dysfunction of the protein C pathway may have important physiopathologic implications in the development of pulmonary fibrosis in ILD. Key Words: Collagen synthesis&mdash;Activated protein C&mdash;Coagulation&mdash; Interstitial lung disease.
Components of the coagulation pathways can influence the inflammatory response and tissue remodeling. Coagulation mechanisms are activated at sites of inflammation, and extravascular fibrin formation usually occurs at foci of tissue injury (1) . Recent studies suggested that activation of the coagulation cascade and fibrin deposition in the alveolar space play important roles in the pathogenesis of interstitial lung disease (ILD) and pulmonary fibrosis (2) . Clot and fibrin deposition in the interstitium and intraalveolar space of the lung may serve as a matrix upon which fibroblasts may proliferate and secrete collagen (3, 4) . Pathologic observations have demonstrated a correlation between persistent fibrin deposits and subsequent pulmonary fibrosis (5) . Hypercoagulability results from the disruption of the balance between the procoagulant and anticoagulant factors. The most important anticoagulant system is the protein C (PC) pathway (6, 7) . Recently, we reported data suggesting that the anticoagulant PC pathway may regulate coagulative processes in the intraalveolar space of the lung of normal subjects and that PC intraalveolar anticoagulant activity is decreased in patients with ILD (8) . This dysfunction of the PC pathway in the intraalveolar space may be responsible for sustained activation of coagulation and persistent fibrin formation in fibroproliferative processes of the lung. To demonstrate this thesis, in the present study, we evaluated the relationship between the activation of the PC pathway and the activity of collagen synthesis in the intraalveolar space of patients with ILD. .
METHODS
Twenty-two patients with ILD were enrolled in the present study. There were five patients (all male) with idiopathic pulmonary fibrosis (IPF), nine (four male, five female) with sarcoidosis-associated ILD, and eight (all female) with collagen vascular disease-associated ILD (CVD-ILD). The diagnosis of IPF was based on the presence of unexplained dyspnea, progressive bilateral pulmonary infiltrates, and evidence of pulmonary fibrosis in histologic specimens obtained by transbronchial or open lung biopsy. The diagnosis of sarcoidosis was established by histologic evidence of noncaseating granulomas in transbronchial lung biopsy specimens and compatible clinical, serologic, and radiographic findings. The diagnosis of CVD-ILD was based on previously reported criteria for each group of CVD and the histologic evidence of pulmonary fibrosis in transbronchial lung biopsy specimens. In all patients, pulmonary function tests, including vital capacity and diffuse lung capacity, were measured using a volume-type spirometer (Chestac-55V)(Chest MI Co.; Tokyo, Japan). Data obtained in five age-matched healthy nonsmoking volunteers served as controls. Written informed consent was obtained from all subjects. The study protocol was approved by the Mie University Hospital Institutional Review Board and it was carried out following the principles of the Helsinki Declaration.
Sampling of bronchoalveolar lavage fluid
Bronchoalveolar lavage was performed as previously described (9) . Briefly, a fiberoptic bronchoscope (Olympus 1T10)(Olympus; Tokyo, Japan) was wedged into a segmental bronchus of the middle lobe or lingula. Four 50-mL aliquots of warmed sterile normal saline were instilled and retrieved immediately by suction at low negative pressure adjusted by a vacuum regulator. The pooled bronchoalveolar lavage fluid (BALF) was collected on ice and processed within 1 hour. The total amount of recovered fluid was measured and the recov-ery rate was calculated. The fluid was filtered through two layers of sterile gauze and centrifuged at 150 g for 10 minutes at 4°C. The cell-free supernatant was separated and stored in small aliquots at -80°C until analysis.
Laboratory analyses
As a marker of coagulation activation, the BALF level of thrombin-antithrombin complex (TAT) was measured using the Enzymun-Test (Boehringer Mannheim; Mannheim, Germany) immunoassay kit following the manufacturer's instructions. The concentration of PC in BALF was determined by a solid-phase immunoassay using a polyclonal anti-human PC and biotin-labeled monoclonal anti-PC antibodies following previously described methods (10) . PC values in BALF were extrapolated from a standard curve drawn using normal standards of PC. The intra-assay and interassay coefficients of variation for PC were 5% and 6%, respectively. Activated PC-PC inhibitor (APC-PCI) complex, a marker of ongoing PC activation, was measured in BALF by an enzyme-linked immunoassay using anti-PCI and peroxidase-conjugated anti-PC monoclonal antibodies as previously described (10) . The antibodies used in the APC-PCI assay do not measure free PC or PCI. The interassay and the intra-assay coefficients of variation were 5% and 7%, respectively. Concentrations of the aminoterminal propeptide of type III procollagen (PIIINP), a marker of ongoing type III collagen synthesis, were determined usz ing a radioimmunoassay kit (Orion Diagnostica; Oulun-.. salo, Finland) (11, 12) . The intra-and interassay variations were less than 10%. Protein concentration in BALF was measured by the Bradford method using the Bio-Rad protein assay kit (Bio-Rad Laboratories; Hercules, CA). FIG. 1. TAT, APC-PCI complex, APC-PCI/PC ratio, and propeptides of type III procollagen in ILD patients. The markers of PC activation, APC-PCI complex and the APC-PCI/ratio, were significantly decreased, and the levels of TAT and PIIINP were significantly increased in BALF from ILD patients (white columns) as compared to controls (black columns). *P=0.03;tP<0.04; and #P= 0.002, versus control.
FIG. 2. Relationship of markers of coagulation and PC activa-
tion with PIIINP in patients with ILD. The BALF concentrations of PIIINP were significantly and proportionally correlated with the BALF levels of TAT (r= +0.7; P = 0.0007) but inversely correlated with the concentrations of APC-PCI complex (r= -0.4; P= 0.02) and with the values of APC-PCI/PC ratio (r= -0.5; P = 0.02).
Statistical analyses
Data were expressed as the mean ± the standard error (SE) unless otherwise specified. The statistical difference between two variables was calculated using the Wil-coxon rank test and the Kruskal-Wallis analysis of variance was used for calculating the difference among the means of three or more variables. The strength of correlation between variables was calculated by the Pearsonproduct moment correlation or by the Spearman correlation according to the distribution of the data. A P < 0.05 was considered as statistically significant.
The predicted values of the vital capacity and diffuse lung capacity were 85.8% ± 4.7% and 46.3% ± 7.3% in ILD patients and 95.9% ± 6.1 % and 92.9% ± 2.1 % in healthy subjects, respectively. The concentration of total protein ( 19.4 ± 2.7 vs 9.4 ± 2.1 mg/dL) was significantly higher in ILD patients than in controls. The marker of coagulation activation, TAT, was significantly increased in BALF from ILD patients (1.7 ± 0.087 I-Lg/mL) as compared to control subjects (1.4 ± 0.07 I-Lg/mL) ( Fig.  1 ). BALF concentrations of PC antigen tended to be higher in patients with ILD (822.0 ± 190.0 ng/mL) than in control subjects (346.0 ± 229.1 ng/mL). The markers of PC activation, APC-PCI complex (377.3 ± 69.2 pg/ mL vs 836.6 ± 251.6 pg/mL; P = 0.03) and APC-PCI/ ratio ( 1.5 ± 0.4 vs 5.1 ± 4.4; P = 0.04) were significantly decreased in BALF from ILD patients as compared to controls (Fig. 1 ). BALF concentrations of propeptides released during type III collagen synthesis, PIIINP (1.7 ± 0.4 )JLg/L vs 0 I-Lg/ml; P = 0.002), were significantly elevated in patients with ILD as compared to healthy subjects (Fig 1 ) . The levels of PIIINP were undetectable in healthy subjects even after concentration of the samples or after modifying the assay for increasing its sensitivity. The BALF concentration of PIIINP was significantly and proportionally correlated with the concentrations of PC antigen (r = +0.8; P = 0.0004) and TAT (r = +0.7; P = 0.0007) (Fig. 2) . In contrast, the BALF concentrations of PIIINP were significantly and inversely correlated with the concentrations of APC-PCI complex (r = -0.4; P = 0.02) and with the values of APC-PCI/PC ratio (r = -0.5; P = 0.02) (Fig. 2 ). ' ILD is a heterogenious group of inflammatory disorders characterized by inflammatory changes of the interstitial and alveolar compartments of the lung with mesenchymal cell proliferation, extracellular matrix deposition, and scarring resulting in progressive loss of normal lung tissue (13) . Systemic disorders such as collagen vascular diseases (CVD-ILD) and sarcoidosis are frequently associated with ILD; IPF is the group of ILDs in which the pathogenesis of the alveolitis and pulmonary fibrosis is unknown. ILD leads ultimately to the development of pulmonary fibrosis which is characterized by excessive amounts of collagen in the lung (14) . Immu-nohistochemical staining of the different collagen types suggests an increase in type I collagen in areas of established fibrous tissue and a tendency for higher proportion of type III collagen in areas of early fibrosis (14) . In the present study, we found increased BALF levels of PIIINP in patients with ILD, suggesting that increased formation of type III collagen occurs in diseases associated with lung fibrosis. This latter may occur nonuniformly ; that is, normal lung tissues with active collagen destruction may exist immediately adjacent to areas with increased collagen deposition.
DISCUSSION
A great body of evidence suggests that increased coagulation activation and abnormal fibrin turnover favors the formation of fibrous tissue in the intraalveolar space in patients with ILD (1, 2, 15) . In accord with this, in the current study, the marker of coagulation activation, TAT, was found to be significantly increased in patients with ILD as compared to normal controls. In the normal lung, coagulation system is inhibited by anticoagulant factors and fibrin is rapidly cleared from the airways (16) . This fibrin clearance occurs because the bronchoalveolar fluid from normal individuals contains urokinase plasminogen activator, which converts plasminogen to plasmin, the active enzyme of the fibrinolytic system. However, procoagulant activity is increased and fibrinolysis is concurrently impaired in acute lung injury and ILD (17) . This depressed fibrinolysis has been associated with increased activity of plasminogen activator inhibitor-I and antiplasmins, including a2-antiplasmin (1) . APC, besides its anticoagulant function, may also stimulate fibrinolysis by its ability to form a complex with or to degrade plasminogen activator inhibitor-1; thus, depressed intraalveolar APC activity may be associated with decreased urokinase activity due to high local concentrations of plasminogen activator inhibitor-1 (18) . In the present study, we found for the first time that the indicator of early collagen turnover, PIIINP, is inversely correlated with markers of PC activation in patients with ILD. These findings suggest that decreased anticoagulant and profibrinolytic activities of APC favor the deposition of fibrin and collagen in the intraalveolar space of patients with ILD.
